At the end of Q1 2026, 23 institutions reported holding Mink Therapeutics Inc. (INKT) in their 13F filings, down 1 from Q4 2025. 3 opened new positions and 5 sold out. The largest holders were Vanguard Capital Management LLC ($625K), Geode Capital Management, LLC ($183K) and Longbow Finance SA ($176K).
Company
Mink Therapeutics Inc.
CUSIP
603693201
Latest filing quarter
Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
Institutions
Total Value
New Positions
3
$23K
Exits
5
$409K
All 13F filers, Q4 2025 → Q1 2026: 10,962 shares bought and 37,182 shares sold, net −26,220 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.